Cosmetics DNA Protein 
Pharmaceutical Technology
MARCH 1, 2023
The drug candidate targets DNA-dependent protein kinase (DNA-PK). The drug candidate is administered through the oral route in the form of capsule and tablet. It is a new chemical entity. It was also under development for small cell lung cancer, rectal cancer and chronic lymphocytic leukemia (CLL).
Pharmaceutical Technology
MARCH 1, 2023
The drug candidate targets DNA-dependent protein kinase (DNA-PK). The drug candidate is administered through the oral route in the form of capsule and tablet. It is a new chemical entity. It was also under development for small cell lung cancer, rectal cancer and chronic lymphocytic leukemia (CLL).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
SEPTEMBER 9, 2024
Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.
FDA Law Blog
DECEMBER 8, 2022
labeling of major food allergens in bulk foods, dietary supplements, protein-free ingredients, and foods produced through genetic engineering); and. labeling of major food allergens in bulk foods, dietary supplements, protein-free ingredients, and foods produced through genetic engineering); and. Other technical labeling matters.
XTalks
APRIL 18, 2023
The plant, which will be one of the first of its kind in the US, will be used to produce plant-based proteins and other ingredients for the food industry. Perfect Day Perfect Day uses precision fermentation to produce animal-free dairy proteins, including whey and casein, in products like ice cream. It has raised a total of $114.3
Roots Analysis
AUGUST 15, 2023
Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.
Pfizer
AUGUST 15, 2022
In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. 07.27.2022.
Expert insights. Personalized for you.
100 
Let's personalize your content